Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rigosertib vs Physician’s Choice in MDS After HMA Failure
DRKS00011259Phase 3Recruiting
- Sponsor
- Onconova Therapeutics, Inc.
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of rigosertib in myelodysplastic syndrome (MDS) (2 arms), sponsored by Onconova Therapeutics, Inc. Primary endpoint: overall survival. Started Nov 2016; status: recruiting.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on DRKS00011259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00011259.